Autoimmune Disorders : Symptoms, Diagnosis and Treatment.
Petrov, Maria E.
Autoimmune Disorders : Symptoms, Diagnosis and Treatment. - 1st ed. - 1 online resource (342 pages) - Immunology and Immune System Disorders . - Immunology and Immune System Disorders .
Intro -- AUTOIMMUNE DISORDERS: SYMPTOMS, DIAGNOSIS AND TREATMENT -- AUTOIMMUNE DISORDERS: SYMPTOMS, DIAGNOSIS AND TREATMENT -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter 1 Autoimmune Liver Diseases -- Abstract -- Autoimmune Hepatitis -- Introduction -- Clinical Presentation -- Pathogenesis -- Diagnosis -- Interpretation of Aggregate Scores -- Treatment -- Alternative Treatments -- AIH and Pregnancy -- Liver Transplantation -- Recurrence of AIH after Liver Transplantation -- Primary Biliary Cirrhosis -- Introduction -- Clinical Presentation of PBC -- Fatigue -- Pruritus -- Associated disorders -- Physical findings -- Portal hypertension -- Metabolic bone disease -- Vitamin deficiency -- Hyperlipidemia -- Urinary tract infections -- Pathogenesis -- Diagnostic Criteria -- Treatment of PBC -- Effects of UDCA therapy -- Management of Symptoms -- Liver Transplantation -- Follow-up -- Primary Sclerosing Cholangitis -- Introduction -- Clinical Presentation -- Pathogenesis -- Diagnosis -- Treatment -- Endoscopic therapy -- Liver transplantation -- Immunoglobulin G4-Associated Cholangitis -- Introduction -- Clinical Presentation -- Diagnosis -- Treatment -- Overlap Syndrome -- Introduction -- Etiology and Pathogenesis -- Diagnosis -- Treatment -- Overlap of Primary Sclerosing Cholangitis and Autoimmune Hepatitis -- Conclusion -- References -- Chapter 2 Immunopathological Events in an Experimental Autoimmune Kidney Disease and How Those Events Can be Terminated to Regain Tolerance to Self -- Abstract -- Introduction -- Background to Heymann Nephritis (HN) -- Fate of rKF3 aag under Physiological Conditions -- Fate of Native rKF3 and Altered rKF3 Aags During Pathological Response to Altered rKF3 aag. Fate of Altered and Native rKF3 Aags during Treatment with ICs Inducing Nonpathogenic Aab Response in Rats with SPHN -- Renal ags Capable of Initiating and Maintaining HN (When Adjuvanted or Modified) -- Nephritogenic aags with the Potential to Induce HN - if Chemically or otherwise Modified - Are Present in the Following Locations -- Where Does the Nephritogenic aag Reside and Where Is It Produced? -- What is a Nephritogenic Aag? -- An Autoimmune Disease Process Can Be Exacerbated -- An Autoimmune Disease Process Can be Downregulated -- Immunological approaches applied to downregulate autoimmune disease causing processes -- Conclusion -- List of Abbreviations -- Acknowledgment -- References -- Chapter 3 Hematopoietic Stem Cell Transplantation for Severe Autoimmune Diseases: Time for a Reappraisal -- Summary -- Introduction -- Allogeneic Transplantation -- Autologous Transplantation: Progress and Questions -- Conclusion -- References -- Chapter 4 Thyroid Arterial Embolization for the Treatment of Graves' Hyperthyroidism -- 1. History of Thyroid Arterial Embolization -- 2. Thyroid Anatomy, Hyperthyroidism and Tests of Thyroid Function -- 2.1. Anatomy -- 2.1.1. Thyroid Gland -- 2.1.2. Parathyroid Glands -- 2.2. Dysfunction of the Thyroid Gland -- 2.2.1. Hyperthyroidism -- 2.2.2. Hypothyroidism -- 2.3. Tests of Thyroid Function -- 2.3.1. Basal Metabolic Rate -- 2.3.2. Thyroidal Radioiodide Uptake -- 2.3.3. Thyroid Releasing Factor Stimulation Test -- 2.3.4. Circulating Thyroxine and Triiodothyronine -- 2.3.5. Resin Triiodothyronine Uptake (rT3) -- 2.3.6. Thyroid Suppression Test -- 2.3.7. Thyrotropin Stimulation Test -- 2.3.8. Thyroid Autoantibodies -- 2.3.9. Thyroid Biopsy -- 3. Thyroid Arterial Embolization for the Treatment of Graves' Hyperthyroidism -- 3.1. Introduction -- 3.2. Preembolization Preparation. 3.3. Blood Supply of the Thyroid Gland and the Parathyroid Gland -- 3.4. Embolization Protocol -- 3.5. Postembolization Management -- 3.6. Efficacy Assessment -- 3.7. Undesirable or Side Effects -- 3.8. Case Report -- 4. Embolization Techniques -- 4.1. Mechanism of Thyroid Arterial Embolization -- 4.2. Scope of Embolization -- 4.3. Thyroid Arteries to be Embolized -- 4.4 Embolizing Techniques -- 4.5. Use of Pingyangmycin -- 4.6. Embolic Materials and Recurrence -- 5. Body Reaction to Thyroid Arterial Embolization -- 5.1. Pathologic and Histologic Features of the Embolized Thyroid Tissues -- 5.2. Changes of Thyroid and Autoimmune Function Caused by Embolization -- 5.2.1. Long-Term Thyroid Function Changes -- 5.2.2. Long-Term Autoimmune Function Changes -- 5.2.2.1 Changes of the Serum Level of Thyroid Autoantibodies -- 5.2.2.2. Measurement of Subgroup Peripheral Blood Lymphocytes -- 5.3. Angiogenic Changes in the Thyroid Caused by Thyroid Arterial Embolization -- 5.4. Apoptotic Changes -- References -- Chapter 5 New Targets and Approaches to Autoimmune-Induced Salivary Hypofunction -- Introduction -- Diagnosis of SS -- Current Treatment Strategies -- Pathogenesis of SS -- Animal Models for SS Pathogenesis -- Dysregulation of Glandular Epithelial Cells: a Potential Role for Reactive Oxygen and Nitrogen Species -- Proteasome Defects in SS -- Potential Future Treatments -- Summary -- References -- Chapter 6 Systemic Lupus Erythematosus: Definition, Pathogenesis and Treatment -- Abstract -- Introduction -- Incidence and Prevalence of SLE Around the World -- Sle Classification Criteria -- Clinical Presentation -- Lupus and Pregancy -- Pathogenesis -- Differential Diagnosis -- SLE Activity Indices -- Damage Index -- Treatment -- SLE Prognosis -- Conclusion -- References. Chapter 7 Diagnosis and Pathogenesis of Neuropsychiatric Syndromes of Systemic Lupus Erythematosus (NPSLE) -- Abstract -- 1. Introduction -- Diagnosis of NPSLE -- 1.1. Neuroimaging -- 1.2. Cytokines -- 1.3. Chemokines -- 2. Pathophysiolgy and Therapeutic Strategies of NPSLE -- 3. Conclusion -- References -- Chapter 8 Cytomegalovirus-Induced Autoimmunity -- Abstract -- 1. The Virus -- 2. Clinical Significance of HCMV Infection -- 2.1. Congenital Infection -- 2.2. HCMV Mononucleosis -- 2.3. HCMV Disease in Immunosuppressed Patients -- 2.4. HCMV Infection in Patients with Autoimmune Disorders -- 3. HCMV Infection and Autoimmunity -- 3.1. Induction of Autoantibodies -- 3.2. HCMV as a Potential Trigger of Autoimmune Disorders -- 3.2.1 Vasculitides and scleroderma -- 3.2.2 Autoimmune encephalitis -- 3.2.3 Post-transplant diabetes mellitus -- 3.3. Active HCMV Infection in Autoimmune Disorders -- 3.3.1. Ulcerative colitis -- 3.3.2 Autoimmune disorders with major vascular involvement -- vasculitis and systemic sclerosis -- 3.3.3 Other autoimmune diseases -- 4. Generation of HCMV-Induced Immunopathology -- 4.1. Humoral Autoimmune Phenomena -- 4.2. HCMV-Induced Inflammation -- 4.2.1 Generation of CD4+ CD28null T cells -- 4.2.2. NF-kB and other inflammation factors -- 4.2.3 Antigen presenting cell paralysis -- 4.3. Vascular Damage -- 5. Anti-HCMV Therapy: Effect on Immunopathology -- 6. Conclusion -- References -- Chapter 9 Behçet's Disease: Symptoms, Diagnosis and Treatment -- Abstract -- Introduction -- Epidemiology -- Etiology and Pathogenesis -- Clinical Features -- Neuro-Behçet's Disease -- Diagnosis and Differentiation from other Conditions -- Differential Diagnosis -- Laboratory Findings -- Treatment -- Topical Treatment -- Systemic Treatment (Table 3) -- Prognosis -- References. Chapter 10 Immunomodulators as Therapeutic Strategies for Managing Multiple Sclerosis -- Abstract -- I. Introduction -- II. MS and Immunological System -- A. Phosphodiesterase Inhibitors (Pdei) -- B. Glatiramer Acetate (Copaxone) -- C. Interferons Beta -- D. Neuropeptides -- III. Conclusion -- References -- Chapter 11 Premenstrual Syndrome: A Disease with an Autoimmune Component? -- Abstract -- Introduction -- Cutaneous Disease and the Menstrual Cycle -- Autoimmune Diseases of the Skin and the Premenstrual Period -- Estrogen and Autoimmunity -- PMS, Autoimmune Diseases, and the Skin -- Potential Mechanisms for an Autoimmune Etiology of PMS -- Conclusions -- References -- Chapter 12 The Primary Target Antigenic Site in Heymann Nephritis is the Renal Proximal Convoluted Tubules' Brush Border Associated Zone of Cells -- Abstract -- Introduction -- Fate of Released Nephritogenic aag from the Renal Proximal Convoluted Tubules during Normal Healthy State -- Notable Observations Made During the Course of SPHN -- Induction and Maintenance of SPHN in Rats -- Termination of Autoimmune Disease Causing Processes in SPHN Utilizing the MVT -- Conclusion -- List of Abbreviations -- Acknowledgment -- References -- Chapter 13 Dysregulation of Autoimmunity Caused by Silica Exposure: Fas-Mediated Apoptosis in T Lymphocytes Derived from Silicosis Patients -- Abstract -- Silicosis and Dysregulation of Autoimmunity -- Fas and Fas-related Molecules Found in Silicosis Patients -- Treg Status in Silicosis -- Conclusion -- Acknowledgments -- References -- Chapter 14 Unusual Renal Localization of Vasculitis in Sjögren's Syndrome: A Clinical Case Report -- Abstract -- Introduction -- Case Report -- Conclusion -- List of Abbreviations -- References -- Index.
9781617616983
Autoimmune diseases.
Autoimmunity.
Electronic books.
RC600 -- .A8355 2011eb
616.97/8
Autoimmune Disorders : Symptoms, Diagnosis and Treatment. - 1st ed. - 1 online resource (342 pages) - Immunology and Immune System Disorders . - Immunology and Immune System Disorders .
Intro -- AUTOIMMUNE DISORDERS: SYMPTOMS, DIAGNOSIS AND TREATMENT -- AUTOIMMUNE DISORDERS: SYMPTOMS, DIAGNOSIS AND TREATMENT -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter 1 Autoimmune Liver Diseases -- Abstract -- Autoimmune Hepatitis -- Introduction -- Clinical Presentation -- Pathogenesis -- Diagnosis -- Interpretation of Aggregate Scores -- Treatment -- Alternative Treatments -- AIH and Pregnancy -- Liver Transplantation -- Recurrence of AIH after Liver Transplantation -- Primary Biliary Cirrhosis -- Introduction -- Clinical Presentation of PBC -- Fatigue -- Pruritus -- Associated disorders -- Physical findings -- Portal hypertension -- Metabolic bone disease -- Vitamin deficiency -- Hyperlipidemia -- Urinary tract infections -- Pathogenesis -- Diagnostic Criteria -- Treatment of PBC -- Effects of UDCA therapy -- Management of Symptoms -- Liver Transplantation -- Follow-up -- Primary Sclerosing Cholangitis -- Introduction -- Clinical Presentation -- Pathogenesis -- Diagnosis -- Treatment -- Endoscopic therapy -- Liver transplantation -- Immunoglobulin G4-Associated Cholangitis -- Introduction -- Clinical Presentation -- Diagnosis -- Treatment -- Overlap Syndrome -- Introduction -- Etiology and Pathogenesis -- Diagnosis -- Treatment -- Overlap of Primary Sclerosing Cholangitis and Autoimmune Hepatitis -- Conclusion -- References -- Chapter 2 Immunopathological Events in an Experimental Autoimmune Kidney Disease and How Those Events Can be Terminated to Regain Tolerance to Self -- Abstract -- Introduction -- Background to Heymann Nephritis (HN) -- Fate of rKF3 aag under Physiological Conditions -- Fate of Native rKF3 and Altered rKF3 Aags During Pathological Response to Altered rKF3 aag. Fate of Altered and Native rKF3 Aags during Treatment with ICs Inducing Nonpathogenic Aab Response in Rats with SPHN -- Renal ags Capable of Initiating and Maintaining HN (When Adjuvanted or Modified) -- Nephritogenic aags with the Potential to Induce HN - if Chemically or otherwise Modified - Are Present in the Following Locations -- Where Does the Nephritogenic aag Reside and Where Is It Produced? -- What is a Nephritogenic Aag? -- An Autoimmune Disease Process Can Be Exacerbated -- An Autoimmune Disease Process Can be Downregulated -- Immunological approaches applied to downregulate autoimmune disease causing processes -- Conclusion -- List of Abbreviations -- Acknowledgment -- References -- Chapter 3 Hematopoietic Stem Cell Transplantation for Severe Autoimmune Diseases: Time for a Reappraisal -- Summary -- Introduction -- Allogeneic Transplantation -- Autologous Transplantation: Progress and Questions -- Conclusion -- References -- Chapter 4 Thyroid Arterial Embolization for the Treatment of Graves' Hyperthyroidism -- 1. History of Thyroid Arterial Embolization -- 2. Thyroid Anatomy, Hyperthyroidism and Tests of Thyroid Function -- 2.1. Anatomy -- 2.1.1. Thyroid Gland -- 2.1.2. Parathyroid Glands -- 2.2. Dysfunction of the Thyroid Gland -- 2.2.1. Hyperthyroidism -- 2.2.2. Hypothyroidism -- 2.3. Tests of Thyroid Function -- 2.3.1. Basal Metabolic Rate -- 2.3.2. Thyroidal Radioiodide Uptake -- 2.3.3. Thyroid Releasing Factor Stimulation Test -- 2.3.4. Circulating Thyroxine and Triiodothyronine -- 2.3.5. Resin Triiodothyronine Uptake (rT3) -- 2.3.6. Thyroid Suppression Test -- 2.3.7. Thyrotropin Stimulation Test -- 2.3.8. Thyroid Autoantibodies -- 2.3.9. Thyroid Biopsy -- 3. Thyroid Arterial Embolization for the Treatment of Graves' Hyperthyroidism -- 3.1. Introduction -- 3.2. Preembolization Preparation. 3.3. Blood Supply of the Thyroid Gland and the Parathyroid Gland -- 3.4. Embolization Protocol -- 3.5. Postembolization Management -- 3.6. Efficacy Assessment -- 3.7. Undesirable or Side Effects -- 3.8. Case Report -- 4. Embolization Techniques -- 4.1. Mechanism of Thyroid Arterial Embolization -- 4.2. Scope of Embolization -- 4.3. Thyroid Arteries to be Embolized -- 4.4 Embolizing Techniques -- 4.5. Use of Pingyangmycin -- 4.6. Embolic Materials and Recurrence -- 5. Body Reaction to Thyroid Arterial Embolization -- 5.1. Pathologic and Histologic Features of the Embolized Thyroid Tissues -- 5.2. Changes of Thyroid and Autoimmune Function Caused by Embolization -- 5.2.1. Long-Term Thyroid Function Changes -- 5.2.2. Long-Term Autoimmune Function Changes -- 5.2.2.1 Changes of the Serum Level of Thyroid Autoantibodies -- 5.2.2.2. Measurement of Subgroup Peripheral Blood Lymphocytes -- 5.3. Angiogenic Changes in the Thyroid Caused by Thyroid Arterial Embolization -- 5.4. Apoptotic Changes -- References -- Chapter 5 New Targets and Approaches to Autoimmune-Induced Salivary Hypofunction -- Introduction -- Diagnosis of SS -- Current Treatment Strategies -- Pathogenesis of SS -- Animal Models for SS Pathogenesis -- Dysregulation of Glandular Epithelial Cells: a Potential Role for Reactive Oxygen and Nitrogen Species -- Proteasome Defects in SS -- Potential Future Treatments -- Summary -- References -- Chapter 6 Systemic Lupus Erythematosus: Definition, Pathogenesis and Treatment -- Abstract -- Introduction -- Incidence and Prevalence of SLE Around the World -- Sle Classification Criteria -- Clinical Presentation -- Lupus and Pregancy -- Pathogenesis -- Differential Diagnosis -- SLE Activity Indices -- Damage Index -- Treatment -- SLE Prognosis -- Conclusion -- References. Chapter 7 Diagnosis and Pathogenesis of Neuropsychiatric Syndromes of Systemic Lupus Erythematosus (NPSLE) -- Abstract -- 1. Introduction -- Diagnosis of NPSLE -- 1.1. Neuroimaging -- 1.2. Cytokines -- 1.3. Chemokines -- 2. Pathophysiolgy and Therapeutic Strategies of NPSLE -- 3. Conclusion -- References -- Chapter 8 Cytomegalovirus-Induced Autoimmunity -- Abstract -- 1. The Virus -- 2. Clinical Significance of HCMV Infection -- 2.1. Congenital Infection -- 2.2. HCMV Mononucleosis -- 2.3. HCMV Disease in Immunosuppressed Patients -- 2.4. HCMV Infection in Patients with Autoimmune Disorders -- 3. HCMV Infection and Autoimmunity -- 3.1. Induction of Autoantibodies -- 3.2. HCMV as a Potential Trigger of Autoimmune Disorders -- 3.2.1 Vasculitides and scleroderma -- 3.2.2 Autoimmune encephalitis -- 3.2.3 Post-transplant diabetes mellitus -- 3.3. Active HCMV Infection in Autoimmune Disorders -- 3.3.1. Ulcerative colitis -- 3.3.2 Autoimmune disorders with major vascular involvement -- vasculitis and systemic sclerosis -- 3.3.3 Other autoimmune diseases -- 4. Generation of HCMV-Induced Immunopathology -- 4.1. Humoral Autoimmune Phenomena -- 4.2. HCMV-Induced Inflammation -- 4.2.1 Generation of CD4+ CD28null T cells -- 4.2.2. NF-kB and other inflammation factors -- 4.2.3 Antigen presenting cell paralysis -- 4.3. Vascular Damage -- 5. Anti-HCMV Therapy: Effect on Immunopathology -- 6. Conclusion -- References -- Chapter 9 Behçet's Disease: Symptoms, Diagnosis and Treatment -- Abstract -- Introduction -- Epidemiology -- Etiology and Pathogenesis -- Clinical Features -- Neuro-Behçet's Disease -- Diagnosis and Differentiation from other Conditions -- Differential Diagnosis -- Laboratory Findings -- Treatment -- Topical Treatment -- Systemic Treatment (Table 3) -- Prognosis -- References. Chapter 10 Immunomodulators as Therapeutic Strategies for Managing Multiple Sclerosis -- Abstract -- I. Introduction -- II. MS and Immunological System -- A. Phosphodiesterase Inhibitors (Pdei) -- B. Glatiramer Acetate (Copaxone) -- C. Interferons Beta -- D. Neuropeptides -- III. Conclusion -- References -- Chapter 11 Premenstrual Syndrome: A Disease with an Autoimmune Component? -- Abstract -- Introduction -- Cutaneous Disease and the Menstrual Cycle -- Autoimmune Diseases of the Skin and the Premenstrual Period -- Estrogen and Autoimmunity -- PMS, Autoimmune Diseases, and the Skin -- Potential Mechanisms for an Autoimmune Etiology of PMS -- Conclusions -- References -- Chapter 12 The Primary Target Antigenic Site in Heymann Nephritis is the Renal Proximal Convoluted Tubules' Brush Border Associated Zone of Cells -- Abstract -- Introduction -- Fate of Released Nephritogenic aag from the Renal Proximal Convoluted Tubules during Normal Healthy State -- Notable Observations Made During the Course of SPHN -- Induction and Maintenance of SPHN in Rats -- Termination of Autoimmune Disease Causing Processes in SPHN Utilizing the MVT -- Conclusion -- List of Abbreviations -- Acknowledgment -- References -- Chapter 13 Dysregulation of Autoimmunity Caused by Silica Exposure: Fas-Mediated Apoptosis in T Lymphocytes Derived from Silicosis Patients -- Abstract -- Silicosis and Dysregulation of Autoimmunity -- Fas and Fas-related Molecules Found in Silicosis Patients -- Treg Status in Silicosis -- Conclusion -- Acknowledgments -- References -- Chapter 14 Unusual Renal Localization of Vasculitis in Sjögren's Syndrome: A Clinical Case Report -- Abstract -- Introduction -- Case Report -- Conclusion -- List of Abbreviations -- References -- Index.
9781617616983
Autoimmune diseases.
Autoimmunity.
Electronic books.
RC600 -- .A8355 2011eb
616.97/8